AR095386A1 - Péptidos de kntc2 y vacunas que los contienen - Google Patents
Péptidos de kntc2 y vacunas que los contienenInfo
- Publication number
- AR095386A1 AR095386A1 ARP140100928A ARP140100928A AR095386A1 AR 095386 A1 AR095386 A1 AR 095386A1 AR P140100928 A ARP140100928 A AR P140100928A AR P140100928 A ARP140100928 A AR P140100928A AR 095386 A1 AR095386 A1 AR 095386A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- ltc
- kntc2
- methods
- well
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 title abstract 4
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777334P | 2013-03-12 | 2013-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095386A1 true AR095386A1 (es) | 2015-10-14 |
Family
ID=51536362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100928A AR095386A1 (es) | 2013-03-12 | 2014-03-13 | Péptidos de kntc2 y vacunas que los contienen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9597382B2 (OSRAM) |
| EP (1) | EP2970944B1 (OSRAM) |
| JP (1) | JP6295491B2 (OSRAM) |
| KR (1) | KR102213574B1 (OSRAM) |
| CN (1) | CN105164256B (OSRAM) |
| AR (1) | AR095386A1 (OSRAM) |
| AU (1) | AU2014232630B2 (OSRAM) |
| BR (1) | BR112015021828A2 (OSRAM) |
| CA (1) | CA2903139C (OSRAM) |
| DK (1) | DK2970944T3 (OSRAM) |
| ES (1) | ES2739693T3 (OSRAM) |
| IL (1) | IL240701B (OSRAM) |
| MX (1) | MX366365B (OSRAM) |
| RU (1) | RU2671395C2 (OSRAM) |
| SG (2) | SG11201507236XA (OSRAM) |
| TW (1) | TWI658049B (OSRAM) |
| WO (1) | WO2014141683A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008231575A1 (en) | 2007-03-27 | 2008-10-02 | Immunovia Ab | Protein signature/markers for the detection of adenocarcinoma |
| WO2016127249A1 (en) * | 2015-02-09 | 2016-08-18 | Université de Montréal | Novel minor histocompatibility antigens and uses thereof |
| WO2016203414A1 (en) * | 2015-06-16 | 2016-12-22 | Fondazione Città Della Speranza - Onlus | Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use |
| GB201516801D0 (en) * | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| WO2018138110A1 (en) | 2017-01-25 | 2018-08-02 | Ose Immunotherapeutics | Method for manufacturing a stable emulsion for peptide delivery |
| EP4036235A1 (en) * | 2018-02-15 | 2022-08-03 | National University Corporation Asahikawa Medical University | Cancer antigen peptide |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| AU2021356681A1 (en) * | 2020-10-09 | 2023-05-18 | Eureka Therapeutics Inc. | Compositions targeting ndc80/mhc complexes and uses thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| CA2225553A1 (en) | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU6795898A (en) | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| EP1022286A4 (en) | 1997-10-07 | 2003-04-09 | Ono Pharmaceutical Co | POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE |
| WO1999067288A1 (en) | 1998-06-25 | 1999-12-29 | Sumitomo Pharmaceuticals Company, Limited | Tumor antigen peptides originating in cyclophilin b |
| US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| WO2002008765A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Basal cell markers in breast cancer and uses thereof |
| US20090062512A1 (en) * | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2002072631A2 (en) | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Mhc molecule constructs and their usesfor diagnosis and therapy |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| AU2003295328A1 (en) | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| JP2007527193A (ja) | 2002-12-10 | 2007-09-27 | アンドキューブ ソシエタ パー アクシオン シンプリフィー | ケモカインに対する核受容体としてのｔｈａｐタンパク質と、転写調節、細胞増殖、および細胞分化におけるその役割 |
| EP1572118A4 (en) | 2002-12-20 | 2010-07-14 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216 |
| US20050100933A1 (en) | 2003-06-18 | 2005-05-12 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1668354A2 (en) | 2003-09-24 | 2006-06-14 | Oncotherapy Science, Inc. | Method of diagnosing breast cancer |
| EP1757306A4 (en) | 2004-04-09 | 2010-05-19 | Genecare Res Inst Co Ltd | AGENT INDUCING APOPTOSIS SPECIFIC TO CARCINOMA CELLS TARGETING A GENE INVOLVED IN STABILIZING CHROMOSOMES |
| JP2008509654A (ja) | 2004-06-01 | 2008-04-03 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド |
| CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| EP2311983A1 (en) | 2005-02-10 | 2011-04-20 | Oncotherapy Science, Inc. | Method of treating bladder cancer using siRNA |
| EP1874471A4 (en) * | 2005-03-16 | 2008-12-10 | Sidney Kimmel Cancer Ct | METHOD AND COMPOSITIONS FOR PREDICTING DEATH BY CANCER AND SURVIVAL OF PROSTATE CANCER USING GENE EXPRESSION SIGNATURES |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| CN101283279A (zh) | 2005-07-29 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法 |
| KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
| US7507536B2 (en) * | 2005-10-07 | 2009-03-24 | The Johns Hopkins University | Methylation markers for diagnosis and treatment of ovarian cancer |
| WO2007064743A2 (en) | 2005-11-30 | 2007-06-07 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| CA2638912A1 (en) * | 2006-02-20 | 2007-08-30 | Phylogica Limited | Method of constructing and screening libraries of peptide structures |
| US7695928B2 (en) | 2006-04-10 | 2010-04-13 | Genentech, Inc. | Disheveled PDZ modulators |
| TWI494319B (zh) * | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| MX2010002018A (es) | 2007-08-20 | 2010-05-27 | Oncotherapy Science Inc | Peptido de cdh3 y agente medicinal que comprende al mismo. |
| US9273100B2 (en) * | 2007-11-09 | 2016-03-01 | Board Of Trustees Of Michigan State University | Use of Galerina marginata genes and proteins for peptide production |
| WO2009099580A2 (en) * | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| US20100281003A1 (en) * | 2009-04-02 | 2010-11-04 | New York University | System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions |
| EP2483690A1 (de) | 2009-09-29 | 2012-08-08 | Protagen AG | Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung |
| EA201890895A1 (ru) * | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
| EP3008204B1 (en) * | 2013-06-10 | 2024-03-13 | Iogenetics, LLC. | Mathematical processes for determination of peptidase cleavage |
-
2014
- 2014-03-06 TW TW103107588A patent/TWI658049B/zh not_active IP Right Cessation
- 2014-03-11 JP JP2015545547A patent/JP6295491B2/ja active Active
- 2014-03-11 AU AU2014232630A patent/AU2014232630B2/en not_active Ceased
- 2014-03-11 EP EP14763683.1A patent/EP2970944B1/en active Active
- 2014-03-11 KR KR1020157027357A patent/KR102213574B1/ko not_active Expired - Fee Related
- 2014-03-11 BR BR112015021828A patent/BR112015021828A2/pt not_active Application Discontinuation
- 2014-03-11 US US14/772,003 patent/US9597382B2/en active Active
- 2014-03-11 CN CN201480022294.6A patent/CN105164256B/zh not_active Expired - Fee Related
- 2014-03-11 ES ES14763683T patent/ES2739693T3/es active Active
- 2014-03-11 MX MX2015012012A patent/MX366365B/es active IP Right Grant
- 2014-03-11 SG SG11201507236XA patent/SG11201507236XA/en unknown
- 2014-03-11 RU RU2015143164A patent/RU2671395C2/ru active
- 2014-03-11 WO PCT/JP2014/001350 patent/WO2014141683A1/en not_active Ceased
- 2014-03-11 DK DK14763683.1T patent/DK2970944T3/da active
- 2014-03-11 SG SG10201707316WA patent/SG10201707316WA/en unknown
- 2014-03-11 CA CA2903139A patent/CA2903139C/en active Active
- 2014-03-13 AR ARP140100928A patent/AR095386A1/es unknown
-
2015
- 2015-08-20 IL IL240701A patent/IL240701B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105164256A (zh) | 2015-12-16 |
| RU2671395C2 (ru) | 2018-10-30 |
| CA2903139A1 (en) | 2014-09-18 |
| JP6295491B2 (ja) | 2018-03-20 |
| ES2739693T3 (es) | 2020-02-03 |
| KR20150126390A (ko) | 2015-11-11 |
| WO2014141683A1 (en) | 2014-09-18 |
| EP2970944B1 (en) | 2019-05-08 |
| CN105164256B (zh) | 2018-10-19 |
| US20160008445A1 (en) | 2016-01-14 |
| IL240701A0 (en) | 2015-10-29 |
| HK1214838A1 (en) | 2016-08-05 |
| IL240701B (en) | 2022-02-01 |
| KR102213574B1 (ko) | 2021-02-09 |
| EP2970944A4 (en) | 2017-04-19 |
| RU2015143164A (ru) | 2017-04-13 |
| SG11201507236XA (en) | 2015-10-29 |
| US9597382B2 (en) | 2017-03-21 |
| MX2015012012A (es) | 2016-04-07 |
| DK2970944T3 (da) | 2019-07-22 |
| MX366365B (es) | 2019-07-05 |
| AU2014232630A1 (en) | 2015-09-17 |
| SG10201707316WA (en) | 2017-10-30 |
| AU2014232630B2 (en) | 2020-07-09 |
| TWI658049B (zh) | 2019-05-01 |
| CA2903139C (en) | 2022-07-26 |
| BR112015021828A2 (pt) | 2017-08-29 |
| JP2016511221A (ja) | 2016-04-14 |
| TW201443077A (zh) | 2014-11-16 |
| EP2970944A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095386A1 (es) | Péptidos de kntc2 y vacunas que los contienen | |
| MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
| CY1121691T1 (el) | Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου | |
| CY1124950T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ | |
| EA201690016A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| EA201692103A1 (ru) | Новый метод иммунотерапии нескольких видов опухолевых заболеваний крови, таких как острый миелоидный лейкоз (омл) | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| MX375994B (es) | Composicion farmaceutica que comprende particulas de plga-peg. | |
| MX2013014489A (es) | Peptidos sema5b y vacunas que incluyen los mismos. | |
| MX380003B (es) | Péptidos topk y vacunas que incluyen los mismos. | |
| MX362912B (es) | Péptidos ube2t y vacunas que incluyen los mismos. | |
| CL2021001479A1 (es) | Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391) | |
| MX2014001675A (es) | Peptidos de mphosph1 y vacunas que incluyen los mismos. | |
| CY1122083T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ) | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| EP3981416A3 (en) | Koc1-derived peptide and vaccine including same | |
| MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
| SG10201900879PA (en) | Cdca1-derived peptide and vaccine containing same | |
| EP3848383A3 (en) | Urlc10-derived peptide and vaccine containing same | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| EA202090821A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл | |
| PH12012501935A1 (en) | Ect2 peptides and vaccines including the same | |
| EA201990696A1 (ru) | Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |